Relief reports that its u.s. collaboration partner has filed a new breakthrough therapy designation request for aviptadil

Relief reports that its u.s. collaboration partner has filed a new breakthrough therapy designation request for aviptadil in a subgroup of patients with critical covid-19 with respiratory failure that were also treated with remdesivir and continued to progress geneva, switzerland / accesswire / april 22, 2022 / relief therapeutics holding sa (six:rlf)(otcqb:rlftf)(otcqb:rlfty) ("relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company, nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx"), of its collaboration partner with respect to aviptadil, neurorx, inc. ("neurorx"), has announced that it has filed a new breakthrough therapy designation request with the u.s. food and drug administration ("fda"). according to nrx, the request was based on a post-hoc analysis, focused on a subgroup of patients with critical covid-19 that, in addition to aviptadil or placebo, were also treated with remdesivir and whose respiratory failure due to critical covid-19 continued to progress.
NRXP Ratings Summary
NRXP Quant Ranking